

Israel's Scpio Labs unveils AI-powered solution to fully automate blood morphology

25 July 2025 | News

Scpio's Complete Blood Morphology (CBM®) ushers in a new era of lab automation



Israel headquartered Scpio Labs, developer of Full-Field Cell Morphology imaging and analysis platform, has announced the unveiling of its groundbreaking Complete Blood Morphology (CBM®) analyser.

CBM will bring unprecedented scale, efficiency and standardisation to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics.

To expedite the go-to-market of CBM®, Viola Growth has joined as a new investor with a \$10 million extension to Scpio's Series D funding, bringing the total to \$52 million.

CBM® is built on top of Scpio's proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform current PBS review workflow into an autonomous, standardised, and clinically relevant process, analysing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilising Scpio's Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM® adoption, effectively future-proofing their operations.

Scopio Labs currently has CE-marked and US FDA-cleared digital imaging applications in the market, including applications for peripheral blood smear and bone marrow aspirate analysis.